Achalazja przełyku: objawy, przyczyny, diagnoza, leczenie i dieta przy zwężeniu przełyku

Esophageal achalasia represents a complex motility disorder of the gastrointestinal tract whose precise etiologic mechanisms remain incompletely understood despite extensive research efforts. The core pathophysiological feature involves dysfunction of the lower esophageal sphincter (LES), which under normal physiological conditions should relax during swallowing to permit the passage of ingested material into the stomach. In achalasia, however, this relaxation capacity is lost, resulting in a sustained elevation of resting pressure within the sphincter region. Concurrently, there is a disruption of esophageal peristalsis—contractile waves become irregular or entirely absent, thereby impairing the efficient transit of food. As a consequence of these alterations, the esophageal lumen progressively dilates in the thoracic segment (a condition termed "megaesophagus"), while the distal segment undergoes narrowing due to chronic irritation and fibrotic remodeling. Food residues and liquids accumulating in the dilated portion encounter resistance from the stenotic sphincter, leading to retrograde flow into the proximal esophagus or even oral cavity—a process manifested by a constellation of debilitating clinical symptoms that significantly compromise patients’ quality of life.

The hallmark symptom of achalasia is progressive dysphagia—difficulty swallowing—that eventually impairs the ability to consume both solid and liquid foods. In the early stages of the condition, patients typically experience challenges primarily with dense or solid foods, but as the disorder advances, even liquids become difficult to ingest. Accompanying symptoms often include a burning sensation in the esophagus (heartburn-like discomfort), recurrent regurgitation of undigested food, and episodes of coughing or choking, which may culminate in aspiration pneumonia—a serious inflammatory lung condition caused by the inhalation of gastric or esophageal contents. Prolonged, untreated achalasia—spanning years or even decades—substantially elevates the risk of developing esophageal squamous cell carcinoma. Are there evidence-based preventive strategies that could mitigate the onset of this motility disorder or decelerate its progression?

The effective implementation of preventive strategies necessitates a precise understanding of both risk factors and the primary causes of a given disorder. In the case of esophageal achalasia—a condition characterized by impaired peristalsis and inadequate relaxation of the lower esophageal sphincter (LES)—such measures encounter fundamental limitations. While the pathophysiological mechanism has been partially elucidated (specifically, the degeneration of neuronal cells within the Auerbach’s plexus, resulting in a deficiency of neurotransmitters responsible for LES relaxation), the etiopathogenesis remains undefined. Scientific hypotheses suggest potential contributions from infectious agents (including viral pathogens), genetic predispositions, and autoimmune processes; however, none of these theories has been conclusively validated. This ambiguity precludes the development of targeted preventive interventions. It is also critical to note that achalasia may manifest as a secondary symptom associated with malignancies located in the pancreas, stomach, or pulmonary system. Consequently, any instance of persistent dysphagia—even if seemingly mild—should undergo thorough differential diagnostic evaluation to exclude more serious underlying pathologies.

The identification of achalasia relies on a comprehensive evaluation employing two core diagnostic modalities: radiographic imaging with the administration of a barium-based contrast medium and a thorough endoscopic examination of the upper gastrointestinal tract. During the imaging assessment, significant abnormalities in the structure and luminal diameter of the esophagus become evident, potentially indicating varying degrees of disease progression. Four primary stages of the condition are distinguished—ranging from the initial phase (Stage I) to the advanced stage (Stage IV), where the latter is marked by pronounced, diffuse dilation extending along the entire length of the organ. As with other conditions presenting similar symptomatology, differential diagnosis is imperative to rule out alternative causes of symptoms—particularly malignant neoplasms—which is primarily achieved through precise endoscopic evaluation with biopsy sampling for histopathological analysis.

The management of esophageal achalasia employs a multifaceted therapeutic framework that integrates pharmacological interventions with progressively invasive procedures. Pharmacotherapy primarily aims to reduce the elevated resting pressure of the lower esophageal sphincter—a pathological hypertonicity recognized as a core contributor to symptomatic manifestations. In this context, localized injections of botulinum toxin type A are administered endoscopically to temporarily inhibit neuromuscular transmission and facilitate bolus passage. Non-surgical alternatives include mechanical dilation of the esophageal lumen using specialized bougies constructed from medical-grade metal alloys or high-durability polymers, as well as endoscopic pneumatic balloon dilation. Complementary to these specialized interventions, lifestyle modifications are imperative, including adherence to a semi-liquid diet to minimize bolus obstruction, avoidance of reflux-provoking foods, and systematic stress mitigation, the latter of which has been empirically linked to disease progression in multiple clinical studies.

Achalasia, a chronic esophageal motility disorder, gives rise to substantial swallowing impairments that frequently result in reduced food intake, progressive weight loss, and an elevated risk of malnutrition. Consequently, the development of a dietary regimen that not only furnishes all essential nutrients—particularly high-quality protein—but also accommodates individual swallowing capacities becomes paramount. In advanced cases, the adoption of a semi-solid or pureed diet rich in easily digestible components proves indispensable. Should this dietary approach fail to meet the body’s requirements for micro- and macronutrients, supplementation with specialized nutritional formulations tailored to the patient’s specific metabolic needs may become necessary. Meals should be characterized by small volume yet high nutritional density and palatability to encourage consistent consumption. It is advisable to eliminate high-fat foods (such as fatty meats, blue-veined cheeses, and cream), indigestible items (legumes, cabbage, onions, corn), as well as carbonated beverages and alcohol, all of which may exacerbate symptoms. For bread, easily digestible varieties such as graham or wheat-rye blends are preferred, although whole-grain products—valued for their fiber content—may be incorporated depending on individual tolerance. Optimal culinary techniques include steaming, foil baking, or braising without preliminary frying to minimize esophageal irritation. Below is a sample meal plan featuring five pureed meals per day, designed to meet the needs of individuals with achalasia. However, the degree of food fragmentation and specific product selection must be adjusted according to the patient’s current clinical status. Following successful surgical or interventional treatment (e.g., esophageal dilation), when food reflux subsides, the diet may be gradually expanded to include more solid textures—always within the bounds of personal tolerance. Achalasia, through its debilitating symptoms (such as retrosternal pain, fullness, or regurgitation), contributes significantly to weight loss and nutritional deficiencies. While current therapeutic modalities—including pharmacotherapy, botulinum toxin injections, balloon dilation, or surgery—may require repeated interventions, the rapid advancements in medical science offer hope for the development of permanent solutions that could restore patients to full, unrestricted functionality.